Comment on: "Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis"

Minerva Urol Nephrol. 2022 Jun;74(3):360-362. doi: 10.23736/S2724-6051.22.04948-5.
No abstract available

Publication types

  • Meta-Analysis
  • Systematic Review
  • Comment

MeSH terms

  • Androgen Antagonists / adverse effects
  • Androgen Receptor Antagonists / adverse effects
  • Antineoplastic Agents* / adverse effects
  • Humans
  • Male
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / pathology
  • Receptors, Androgen / therapeutic use

Substances

  • Androgen Antagonists
  • Androgen Receptor Antagonists
  • Antineoplastic Agents
  • Receptors, Androgen